

IMMUCELL CORP /DE/
Form 10-Q
November 12, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2014

001-12934

(Commission file number)

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

Delaware 01-0382980
(State of Incorporation) (I.R.S. Employer
Identification No.)

56 Evergreen Drive, Portland, ME 04103
(Address of principal executive office) (Zip Code)

(207) 878-2770

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of the Registrant’s common stock outstanding at November 7, 2014 was 3,027,034.

ImmuCell Corporation

TABLE OF CONTENTS

September 30, 2014

PART I: FINANCIAL INFORMATION

ITEM 1.	Financial Statements	
	Balance Sheets as of September 30, 2014 and December 31, 2013	2
	Statements of Operations for the three-month and nine-month periods ended September 30, 2014 and 2013	3
	Statements of Comprehensive Income (Loss) for the three-month and nine-month periods ended September 30, 2014 and 2013	4
	Statements of Stockholders' Equity for the nine-month periods ended September 30, 2014 and 2013	5
	Statements of Cash Flows for the nine-month periods ended September 30, 2014 and 2013	6
	Notes to Unaudited Financial Statements	7-12
ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	13-21
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	21
ITEM 4.	Controls and Procedures	21
PART II: OTHER INFORMATION		
ITEMS 1 THROUGH 6		22-26
	Signature	27

ImmuCell Corporation**PART 1.
FINANCIAL
INFORMATION****ITEM 1.
FINANCIAL
STATEMENTS****BALANCE
SHEETS**

	(Unaudited) As of September 30, 2014	As of December 31, 2013
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 1,166,211	\$ 2,270,385
Short-term investments	2,985,000	2,985,000
Inventory	1,039,446	1,206,508
Accounts receivable, net	563,564	631,410
Prepaid expenses and other assets	336,622	159,117
Current portion of deferred tax asset	0	15,212
Total current assets	6,090,843	7,267,632
PROPERTY, PLANT AND EQUIPMENT, net	2,793,624	2,524,765
DEFERRED TAX ASSET	1,340,853	1,154,681
LONG-TERM INVESTMENTS	496,000	0
OTHER ASSETS, net	19,649	13,636
TOTAL ASSETS	\$ 10,740,969	\$ 10,960,714
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accrued expenses	\$ 367,233	\$ 293,076
Accounts payable	241,019	152,153
Deferred tax liability	24,688	0
Current portion of bank debt	185,004	190,390
Deferred revenue	6,690	0
Total current liabilities	824,634	635,619

LONG-TERM LIABILITIES:		
Long-term portion of bank debt	759,964	896,224
Interest rate swap	32,680	33,002
Total long-term liabilities	792,644	929,226
TOTAL LIABILITIES	1,617,278	1,564,845
STOCKHOLDERS' EQUITY:		
Common stock, \$0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued as of September 30, 2014 and December 31, 2013	326,115	326,115
Capital in excess of par value	10,034,566	10,011,339
Accumulated deficit	(705,194)	(407,408)
Treasury stock, at cost, 234,114 and 235,114 shares as of September 30, 2014 and December 31, 2013, respectively	(512,153)	(514,341)
Accumulated other comprehensive loss	(19,643)	(19,836)
Total stockholders' equity	9,123,691	9,395,869
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 10,740,969	\$ 10,960,714

The accompanying notes are an integral part of these financial statements.

ImmuCell Corporation**(Unaudited)****STATEMENTS OF OPERATIONS**

	For the Three-Month Periods Ended September 30,		For the Nine-Month Periods Ended September 30,	
	2014	2013	2014	2013
Product sales	\$1,770,129	\$1,234,701	\$5,391,599	\$4,447,928
Costs of goods sold	692,233	618,984	2,285,285	1,994,967
Gross margin	1,077,896	615,717	3,106,314	2,452,961
Product development expenses	361,232	290,853	1,716,114	829,190
Sales and marketing expenses	373,595	258,237	921,588	725,508
Administrative expenses	302,216	226,594	873,866	707,841
Operating expenses	1,037,043	775,684	3,511,568	2,262,539
NET OPERATING INCOME (LOSS)	40,853	(159,967)	(405,254)	190,422
Other (expenses) revenues, net	(11,246)	236,868	(38,633)	267,646
INCOME (LOSS) BEFORE INCOME TAXES	29,607	76,901	(443,887)	458,068
Income tax (expense) benefit	(19,277)	(19,565)	146,101	(189,970)
NET INCOME (LOSS)	\$10,330	\$57,336	\$(297,786)	\$268,098
Weighted average common shares outstanding:				
Basic	3,027,034	3,019,034	3,026,990	3,019,034
Diluted	3,105,832	3,085,300	3,026,990	3,081,984
NET INCOME (LOSS) PER SHARE:				
Basic	\$0.00	\$0.02	\$(0.10)	\$0.09
Diluted	\$0.00	\$0.02	\$(0.10)	\$0.09

The accompanying notes are an integral part of these financial statements.

ImmuCell Corporation

(Unaudited)

STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

	For the Three-Month Periods Ended September 30,		For the Nine-Month Periods Ended September 30,	
	2014	2013	2014	2013
Net income (loss)	\$ 10,330	\$ 57,336		